A total of 1,693 shareholders were present at the meeting held in
Shareholders approved the 27th consecutive dividend increase since Novartis was founded in 1996, with an increase of 3.1% to
Annual re-election of the members of the Board of Directors
The shareholders elected
They also confirmed all current members of the Compensation Committee for one year. The Board intends to reappoint
Reduction of share capital
In accordance with the recommendation of the Board of Directors, shareholders also approved the cancellation of 87,547,255 shares (purchased under the authorizations of
Vote on the report on non-financial matters
With the introduction of new provisions regarding the transparency of non-financial matters in the Swiss Code of Obligations, Novartis was obliged for the first time for the 2023 financial year to prepare a report on non-financial matters and present it to shareholders. The shareholders approved the report on non-financial matters for the 2023 financial year in an advisory vote.
Votes on the remuneration of the members of the Board of Directors and the Executive Board
In two separate binding votes, the shareholders approved the maximum total remuneration of the Board of Directors from the 2024 Annual General Meeting to the 2025 Annual General Meeting and the maximum total remuneration of the
Election of
In accordance with the Board of Directors' proposal, the shareholders elected
Disclaimer
This communication contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from the anticipated results, performance or achievements reflected in the forward-looking statements or are implied. Some of the risks associated with these statements are summarized in the English language version of this release and
About Novartis
Novartis is a focused company focused on innovative medicines. Every day we work to reimagine medicine to improve and extend people's lives, so that patients, healthcare professionals and society are able to manage serious illnesses. Our medicines reach more than 250 million people worldwide.
Contact:
Tel: +41 61 324 7944
Email: investor.relations@novartis.com
(C) 2024 Electronic News Publishing, source